Close

UPDATE: IDEAYA Biosciences (IDYA) Reports First Patient Dosing in Phase 1 Clinical Trial of MAT2A Inhibitor IDE397 Evaluating MTAP-Deletion Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/20/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SNV
6. SPY
7. INFY
8. SMCI
9. NVDA
10. SLB


Go back to UPDATE: IDEAYA Biosciences (IDYA) Reports First Patient Dosing in Phase 1 Clinical Trial of MAT2A Inhibitor IDE397 Evaluating MTAP-Deletion Solid Tumors
(NASDAQ: IDYA) Delayed: 37.13 -0.49 (1.3%)
Previous Close $37.62    52 Week High $ 
Open $37.38    52 Week Low $ 
Day High $38.30    P/E N/A 
Day Low $36.58    EPS $ 
Volume 726,233